Genfit S.A. (NASDAQ:GNFT - Free Report) - Research analysts at Leerink Partnrs reduced their FY2025 EPS estimates for shares of Genfit in a report issued on Wednesday, February 5th. Leerink Partnrs analyst T. Smith now forecasts that the company will post earnings of ($0.88) per share for the year, down from their previous estimate of ($0.86). The consensus estimate for Genfit's current full-year earnings is $0.95 per share. Leerink Partnrs also issued estimates for Genfit's FY2026 earnings at ($0.84) EPS, FY2027 earnings at ($0.35) EPS and FY2028 earnings at ($0.88) EPS.
Separately, HC Wainwright reissued a "buy" rating and issued a $13.00 target price on shares of Genfit in a research note on Friday.
Check Out Our Latest Stock Analysis on Genfit
Genfit Stock Performance
Shares of NASDAQ GNFT traded down $0.04 during midday trading on Friday, hitting $3.89. The stock had a trading volume of 1,234 shares, compared to its average volume of 8,412. The stock has a 50 day simple moving average of $3.75 and a 200-day simple moving average of $4.43. Genfit has a 1 year low of $3.35 and a 1 year high of $6.42. The company has a debt-to-equity ratio of 0.61, a quick ratio of 3.74 and a current ratio of 3.74.
About Genfit
(
Get Free Report)
Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.
Read More
Before you consider Genfit, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genfit wasn't on the list.
While Genfit currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
